Vir Biotechnology (VIR)

Company Profile

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.

Company profile

Ticker

VIR

Exchange

NASDAQ

Website

www.vir.bio

CEO

George A. Scangos

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...

SEC CIK

0001706431

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Agenovir Corporation • Encentrio Therapeutics, Inc. • Encentrio Therapeutics International GmbH • Humabs BioMed SA • Statera Health, LLC • TomegaVax, Inc. • Vir AU Biotechnology Pty Ltd. • Vir Biotechnology International GmbH • Vir Predictive Medicine, Inc. • VirAb, Inc. ...

IRS number

812730369

VIR stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$52.00

Low target

$30.00

High target

$100.00

Latest filings (excl ownership)

View all

8-K

Regulation FD Disclosure

10 Mar 23

8-K

Amendments to Articles of Incorporation or Bylaws

8 Mar 23

S-8

Registration of securities for employees

28 Feb 23

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Departure of Directors or Certain Officers

16 Feb 23

8-K

Entry into a Material Definitive Agreement

13 Feb 23

8-K

Departure of Directors or Certain Officers

3 Nov 22

Latest ownership filings

View all

VICKI L SATO

9 Mar 23

Johanna Friedl-Naderer

7 Mar 23

Charles Elliott Sigal

Johanna Friedl-Naderer

24 Feb 23

Financial summary

Financial statements Chart VIR financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	867.97 mm	867.97 mm	867.97 mm	867.97 mm	867.97 mm	867.97 mm
Cash burn (monthly)	38.67 mm	(no burn)	50.55 mm	(no burn)	(no burn)	(no burn)
Cash used (since last report)	106.73 mm	n/a	139.52 mm	n/a	n/a	n/a
Cash remaining	761.24 mm	n/a	728.45 mm	n/a	n/a	n/a
Runway (months of cash)	19.7	n/a	14.4	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

VIR institutional ownership history Ownership history

94.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	225	217	+3.7%
Opened positions	41	38	+7.9%
Closed positions	33	32	+3.1%
Increased positions	78	90	-13.3%
Reduced positions	71	54	+31.5%

13F shares	Current	Prev Q	Change
Total value	2.15 tn	2.12 bn	+101226.1%
Total shares	125.78 mm	99.92 mm	+25.9%
Total puts	73.80 k	166.90 k	-55.8%
Total calls	172.10 k	197.30 k	-12.8%
Total put/call ratio	0.4	0.8	-49.3%

Largest owners	Shares	Value	Change
SB Investment Advisers	20.26 mm	$512.77 bn	-8.3%
Softbank Vision Fund	20.26 mm	$0.00	NEW
BLK Blackrock	14.14 mm	$357.80 bn	+1.9%
ARCH Venture Fund IX	12.92 mm	$369.42 mm	0.0%
Vanguard	10.09 mm	$255.49 bn	+1.7%
GSK GSK	6.63 mm	$199.31 mm	0.0%
Temasek	5.71 mm	$144.53 bn	-5.4%
STT State Street	5.48 mm	$138.61 bn	NEW
Baillie Gifford & Co	3.98 mm	$100.85 bn	+0.1%
Alliancebernstein	2.35 mm	$59.58 bn	+0.8%

Largest transactions	Shares	Bought/sold	Change
Softbank Vision Fund	20.26 mm	+20.26 mm	NEW
STT State Street	5.48 mm	+5.48 mm	NEW
SB Investment Advisers	20.26 mm	-1.83 mm	-8.3%
Pacer Advisors	1.10 mm	+1.10 mm	+538818.6%
Avidity Partners Management	850.00 k	+850.00 k	NEW
Norges Bank	728.56 k	+728.56 k	NEW
American Century Companies	1.05 mm	+493.60 k	+88.1%
Renaissance Technologies	1.06 mm	-454.09 k	-30.0%
Skandinaviska Enskilda Banken AB	443.60 k	+443.60 k	NEW
Balyasny Asset Management	0.00	-385.15 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VIR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
8 Mar 23	Sato Vicki L	Common Stock	Sell	Dispose S	No	Yes	22.585	17,935	405.06 k	1,327,324
3 Mar 23	Johanna Friedl-Naderer	Common Stock	Sell	Dispose S	No	No	22.82	1,482	33.82 k	148,518
1 Mar 23	Sigal Charles Elliott	Common Stock	Buy	Acquire P	Yes	Yes	22.7262	2,500	56.82 k	10,000
27 Feb 23	Pang Phillip	Common Stock	Sell	Dispose S	No	Yes	23.5601	1,400	32.98 k	188,000
27 Feb 23	Pang Phillip	Common Stock	Sell	Dispose S	No	Yes	23.0029	8,920	205.19 k	189,400
24 Feb 23	Scangos George A	Common Stock	Sell	Dispose S	No	Yes	23.557	10,880	256.30 k	168,489
24 Feb 23	Scangos George A	Common Stock	Sell	Dispose S	No	Yes	22.737	4,239	96.38 k	179,369
23 Feb 23	Scangos George A	Common Stock	Sell	Dispose S	No	No	25.973	12,631	328.06 k	183,608